Tarsus Reports Third Quarter 2026 Financial Results
Globe Newswire•03/11/2026•16:05 ET
0
Key Highlights
- ➤XDEMVY Q3 net sales $194.6 million, up approximately 64% year-over-year
- ➤XDEMVY surpassed one million bottles dispensed and $1 billion cumulative sales
- ➤Q3 net loss $668.3 million, or $(14.40) per share
- ➤Acquired IPR&D expenses totaled $632.2 million from iRenix and Alkeus acquisitions
- ➤Cash, cash equivalents and marketable securities totaled $309.6 million at September 30
Expert Statements
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus
“Ten years ago, we started Tarsus with the conviction that patients with overlooked diseases deserved better”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus
“XDEMVY has shown what that focus can achieve.”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus
“In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started.”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus
“That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus
“As we become the next leader in eye care, what drives us is the patient still searching for a better treatment and the possibility that our next medicine can provide it.”
Generated record XDEMVY(®) net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year
Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch
Get started
Create a free account to read the full story.